General-purpose frontier labs are moving into territory that purpose-built TechBio companies have spent a decade and billions defending. This piece asks whether that moat is real.
This analysis is now published in full on BioPharmaTrend.
What’s inside:
Where general models already match domain-specific tools, and where they don’t
What Anthropic’s recent releases change for companies with proprietary biological data
The three things that actually constitute a TechBio moat — and why renting data isn’t the same as generating it
Which companies face real pressure from this, and which don’t
ALSO — The numbers behind China’s biopharma ascent: human trial approvals down from 501 days to 87, out-licensing deal value up 54x to $135.7B, and the limits the new ITIF report is careful to flag.
(For BioPharmaTrend subscribers · €8,99/month or €89,90/year).
The refinement I'd add is that "data" and "validation" serve very different roles in that phrase, and the gap between them is where most of the value lies. Proprietary data is necessary and increasingly common. Validated data, calibrated to the biology you're actually drugging, is the rare, capital-intensive part, and it's the only thing that survives the stages Anthropic can't touch: tox, efficacy, patient selection.
Which sharpens @Bengüsu's build-vs-partner point nicely. You can rent a model, and soon everyone will. You cannot rent a validated loop for your specific biology, the thing that tells you whether the data predicts the clinic. That is what a small player with real data and tacit knowledge actually owns, and it's the leverage to set terms before the big labs generate their own.
It also makes the China section the sharper story: speed and enrollment scale are a validation advantage as much as a cost one, more shots and faster readouts, and that compounds exactly where model access doesn't.
Great read. The China angle is gold.